Inclusion Criteria:

          -  Only For B-ALL

               1. No gender or age limit

               2. Histologically confirmed diagnosis of CD69b+ B-ALL per the US National
                  Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for Acute
                  Myeloid Leukemia (2016.v1);

               3. Relapsed or refractory CD123+ AML (meeting one of the following conditions):

                    1. CR not achieved after standardized chemotherapy;

                    2. CR achieved following the first induction, but CR duration is less than 12
                       months;

                    3. Ineffectively after first or multiple remedial treatments;

                    4. 2 or more relapses;

               4. The number of primordial cells in bone marrow is > 5% (by morphology), and/or >
                  0.01% (by flowcytometry);

               5. Philadelphia chromosome negative(Ph-) subjects; Ph+ subjects who cannot tolerate
                  tyrosine kinase inhibitor (TKI) treatment or who do not respond to two kinds of
                  TKI treatment;

          -  Only For B-NHL

               1. No gender or age limit;

               2. Histologically confirmed diagnosis of DLBCL (NOS), FL, DLBCL transformed from
                  CLL/SLL, PMBCL, and HGBCL per the WHO Classification Criteria for Lymphoma
                  (2016);

               3. Relapsed or refractory B-NHL (meeting one of the following conditions):

               1. No response or relapse after second-line or above chemotherapy regimens;

               2. Primary drug resistance;

               3. Relapse after auto-HSCT;

               4. At least one assessable tumor lesion per Lugano 2014 criteria

          -  For both B-ALL and B-NHL

               1. Total bilirubin ≤ 51 umol/L, ALT and AST ≤ 3 times of upper limit ofnormal,
                  creatinine ≤ 176.8 umol/L;

               2. Echocardiogram shows left ventricular ejection fraction (LVEF) ≥50%;

               3. No active infection in the lungs, blood oxygen saturation in indoorair is ≥ 92%;

               4. Estimated survival time ≥ 3 months;

               5. ECOG performance status 0 to 2;

               6. Patients or their legal guardians volunteer to participate in the studyand sign
                  the informed consent.

        Exclusion Criteria:

          -  1. History of craniocerebral trauma, conscious disturbance,epilepsy,cerebrovascular
             ischemia, and cerebrovascular, hemorrhagicdiseases; 2. Electrocardiogram shows
             prolonged QT interval, severe heart diseasessuch as severe arrhythmia in the past; 3.
             Pregnant (or lactating) women; 4. Patients with severe active infections (excluding
             simple urinarytractinfectionand bacterial pharyngitis); 5. Active infection of
             hepatitis B virus or hepatitis C virus; 6. Previously treated with any CAR-T cell
             product or other genetically modified T cell therapies; 7. Insufficient amplification
             capacity in response to CD3 / CD28 co-stimulus signal (<5 times) 8.
             Creatinine>2.5mg/dl, or ALT / AST > 3 times of normal amounts, or bilirubin>2.0 mg/dl;
             9. Other uncontrolled diseases that were not suitable for this trial; 10. Patients
             with HIV infection; 11. Any situations that the investigator believes may increase the
             risk ofpatients or interfere with the results of study.